Drugcen

Abiret 250 Mg (Abiraterone Acetate)

The prostate gland is a tiny organ in males that produces seminal fluids. One of the most common cancers, prostate cancer develops in the prostate gland. Abiret 250 mg has been shown to be effective in the treatment of prostate cancer. Essential medications for prostate cancer, such as Abiret 250mg, can be procured from Drugcen.

Product Name: Abiret 250 mg

Generic Name: Abiraterone Acetate

Most Related Products: Zytix

Order Now

+8801721910505

Description

ABOUT ABIRET 250 Mg 

The active ingredient in Abiret 250mg is Abiraterone Acetate USP 250mg. This medicine is produced and manufactured by Drug International LTD. This medicine is essential and effective medicine against prostate cancer. Abiret 250mg works by  blocking the production of androgens in the body. It reduces the activity of the enzyme 17 beta-hydroxylase 20-lyase (CYP17). This enzyme is essential for androgen biosynthesis, so it is highly expressed in testicular, adrenal, and prostatic tumour tissues. This treatment is recommended for patients with advanced castration-resistant prostate cancer (CRPC) or castration-sensitive prostate cancer (CSPC) with a high risk of metastasis.

DOSAGE

Patients with advanced CRPC are typically prescribed four tablets once daily in addition to two 5mg oral doses of Prednisone. Metastatic high-risk CSPC patients, on the other hand, are advised to take four 250-mg tablets at once in addition to 5 mg of oral Prednisone once daily. You need to get some water and take the capsule whole. Make sure the capsule doesn’t get opened, broken, or chewed.

Side Effects 

  • Drowsiness. 
  • nauseousness. 
  • vomiting. 
  • low potassium levels. 
  •  fever. 
  • cough. 
  •  persistent cold and fluid retention.

STORAGE

Abiret 250mg needs to be kept cool (below 30 degrees Celsius), dark (away from light), and secure location (away from curious hands).

Reviews

There are no reviews yet.

Be the first to review “Abiret 250 Mg (Abiraterone Acetate)”

Your email address will not be published. Required fields are marked *